149 related articles for article (PubMed ID: 12625415)
21. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
22. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
23. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag JB; Walter YH; Nedelman JR; McLeod JF
Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
[TBL] [Abstract][Full Text] [Related]
25. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
26. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
27. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
Mori Y; Kitahara Y; Miura K; Tajima N
Endocrine; 2004 Feb; 23(1):39-43. PubMed ID: 15034195
[TBL] [Abstract][Full Text] [Related]
28. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
Whitelaw DC; Clark PM; Smith JM; Nattrass M
Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
[TBL] [Abstract][Full Text] [Related]
29. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
Sato Y; Nishikawa M; Shinkai H; Sukegawa E
Diabetes Res Clin Pract; 1991 Apr; 12(1):53-9. PubMed ID: 1906797
[TBL] [Abstract][Full Text] [Related]
30. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
[TBL] [Abstract][Full Text] [Related]
31. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
[TBL] [Abstract][Full Text] [Related]
32. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
33. Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in Zucker Fatty rats.
Kajioka T; Miura K; Kitahara Y; Yamagishi S
Horm Metab Res; 2007 Dec; 39(12):889-93. PubMed ID: 17987547
[TBL] [Abstract][Full Text] [Related]
34. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
35. [Preclinical studies of AY4166 (A-4166)].
Kondo N
Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
[No Abstract] [Full Text] [Related]
36. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
[TBL] [Abstract][Full Text] [Related]
37. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of nateglinide response as assessed by insulinogenic indices: preliminary study to determine an optimal indication for nateglinide.
Mori Y; Ishii H; Hikita M; Tajima N
Adv Ther; 2003; 20(6):352-9. PubMed ID: 15058753
[TBL] [Abstract][Full Text] [Related]
39. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
[TBL] [Abstract][Full Text] [Related]
40. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]